Organogenesis HoldingsSTU:2PQ 67 Current Ratio is 3.53 as of Mar. 2026, which is 35% above its 10-year median of 2.62. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.71 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, Organogenesis Holdings ranks better than 73.52% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Organogenesis Holdings's current ratio for the quarter that ended in Mar. 2026 was 3.53.
Organogenesis Holdings has a current ratio of 3.53. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Organogenesis Holdings's Current Ratio or its related term are showing as below:
STU:2PQ'
s Current Ratio Range Over the Past 10 Years
Min: 0.03 Med: 2.62 Max: 7.01
Current: 3.53
During the past 11 years, Organogenesis Holdings's highest Current Ratio was 7.01. The lowest was 0.03. And the median was 2.62.
STU:2PQ's Current Ratio is ranked better than 73.52% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs STU:2PQ: 3.53
Organogenesis Holdings (STU:2PQ) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Organogenesis Holdings Current Ratio Related Terms
Organogenesis Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2PQ vs TKNO, AKBA, SIGA: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (STU:2PQ) has a Current Ratio of 3.53 as of Mar. 2026. This is 35% above median its historical median of 2.62. Over the past decade, Organogenesis Holdings' Current Ratio has ranged from 0.03 to 7.01. According to the industry distribution chart, Organogenesis Holdings ranks #264 out of 997 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Organogenesis Holdings' Current Ratio too high?
Organogenesis Holdings' current Current Ratio of 3.53 is 35% above median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 7.01. The Drug Manufacturers industry median Current Ratio is 2.00. Organogenesis Holdings' value of 3.53 is 76.5% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #264 out of 997 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Current Ratio compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #264 out of 997 companies for Current Ratio. This puts Organogenesis Holdings in the upper half of its industry. The industry median Current Ratio is 2.00. Organogenesis Holdings' value of 3.53 is 76.5% above this benchmark. Historically, Organogenesis Holdings' own Current Ratio has ranged from 0.03 to 7.01 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 2.00, Organogenesis Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Current Ratio of 3.53 is 76.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Current Ratio is 3.53, which is 35% above median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.71, compared to a current price of €2.12 — trading 21.8% below its estimated fair value. The current Current Ratio is 3.53, which is 35% above median its 10-year median of 2.62 and 76.5% above the Drug Manufacturers industry median of 2.00. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current Current Ratio is 3.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.12 is trading 21.8% below its estimated GF Value™ of €2.71.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for STU:2PQ:
Current Ratio: 3.53 (35% above median its 10-year median of 2.62)
GF Value™: €2.71 vs. price of €2.12 (21.8% below fair value)
Industry Position: 76.5% above the Drug Manufacturers median (#264 of 997)
No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score
Get the complete analysis for STU:2PQ
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2PQ has been successfully added to your 
